Latisse approved for treatment of hypotrichosis of the eyelashes

The FDA has approved Allergan’s Latisse (bimatoprost ophthalmic solution) 0.03% for the treatment of hypotrichosis of the eyelashes. Latisse is only available through a doctor as a once-daily prescription treatment applied to the upper eyelashes with a sterile, single-use-per-eye applicator. It enhances eyelash prominence as measured by increases in length, thickness, and darkness of eyelashes in as little as 8 weeks, with full results in 16 weeks. Eyelashes will gradually return to where they were prior to treatment over a period of weeks to months if therapy is discontinued.

Latisse is expected to be available in the first quarter of 2009.

For more information call (800) 433-8871 or visit www.latisse.com.